The European Medicines Agency’s pharmacovigilance risk assessment committee (PRAC) has begun evaluating reports of myocardial infarction following the administration of two coronavirus vaccines, COVID-19 Vaccine Janssen and AstraZeneca PLC/Oxford University’s Vaxzevria. Reports of pulmonary embolism and thromboses with Vaxzevria are also being investigated.
The EMA said PRAC was aware of the results of an epidemiological study based on French national databases and posted...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?